PFE - Pfizer Inc.
| Previous Close | 37.50 |
| Open | 37.65 |
| Bid | 37.66 x 1000 |
| Ask | 37.67 x 900 |
| Day's Range | 37.45 - 37.87 |
| 52 Week Range | 27.88 - 44.56 |
| Volume | 2,827,031 |
| Avg. Volume | 31,785,508 |
| Market Cap | 208.862B |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | 13.43 |
| EPS (TTM) | 2.80 |
| Earnings Date | Jul. 27, 2020 - Jul. 31, 2020 |
| Forward Dividend & Yield | 1.52 (4.05%) |
| Ex-Dividend Date | May 07, 2020 |
| 1y Target Est | 41.36 |
- GlobeNewswire
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced that Pfizer Inc. (PFE) has entered into a stock purchase agreement with ContraFect pursuant to which Pfizer Inc. has agreed to purchase 674,156 shares of ContraFect’s common stock and a warrant to purchase 505,617 shares of ContraFect’s common stock, for approximately $3.0 million in a private placement transaction that is expected to close on May 27, 2020. The private placement is contingent upon the closing of ContraFect’s public offering previously announced on May 21, 2020, and there can be no assurance as to whether or when the private placement may be completed.
- Yahoo Finance
An 'unprecedented' effort to find a coronavirus vaccine has over 100 horses in the race
Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.
- Motley Fool
3 Large-Cap Coronavirus Stocks Still Worth Buying
Abbott Labs (NYSE: ABT) made headlines in late March when the FDA gave emergency use authorization (EUA) for the company's COVID-19 test that runs on its ID NOW platform. Abbott also announced interim results last week from a clinical study in urgent care clinics that showed high levels of sensitivity for positive results and specificity for negative results.
- Yahoo Finance
Some wellness products growing ‘over 1,000%’ during pandemic: Ro CEO
The coronavirus pandemic accelerated a wellness renaissance among consumers as shelter in place orders took effect, based on some of the sales trends seen by companies including Ro.
- Business Wire
Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC
Pfizer Inc. (NYSE: PFE) today announced that it and Wyeth recommend rejection of the unsolicited tender offer made by Huguenot Bond Liquidity, LLC ("Offeror") on May 11, 2020 (as amended and restated on May 21, 2020) to purchase up to $162.5 million principal amount of Pfizer’s outstanding 7.200% notes due 2039 (the "Pfizer Notes") and up to $130.0 million principal amount of Wyeth’s 5.950% notes due 2037 (the "Wyeth Notes" and together with the Pfizer Notes, the "Notes"). Wyeth is a wholly-owned subsidiary of Pfizer. Pfizer and Wyeth do not endorse Offeror’s unsolicited tender offer, and neither Pfizer nor Wyeth is affiliated or associated with the Offeror, the tender offer or the offer documentation. The Offeror did not inform Pfizer of the tender offer, and Pfizer only became aware of the offer through a third party source. Further, there is no disclosure of information regarding the Offeror or any indication as to a source of financing for the offer in the offer documentation.
- Zacks
Is Pfizer (PFE) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Yahoo Finance
Telehealth is going to 'become the default' for patients: Ro CEO
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
- Yahoo Finance
The race for a coronavirus treatment is fanning fears of 'vaccine nationalism'
Geopolitical rivalries, as well as practical considerations, are emerging as real hurdles in the race for a COVID treatment.
- Zacks
Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales
FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.
- Zacks
Coronavirus Vaccine Race Pushes Up Pharma Giants' Production
Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.
- Zacks
AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer
FDA approves AstraZeneca (AZN)/Merck's (MRK) PARP inhibitor Lynparza for HRR gene-mutated metastatic castration-resistant prostate cancer. The approval was based on data from the phase III PROfound study.
- Motley Fool
Pfizer Participates in Funding for Biotech Startup Amplyx
The pharmaceutical major is part of the privately-held company's latest round of capital raising.
- Motley Fool
FDA Approves New Prostate Cancer Treatment From AstraZeneca and Merck
Members of a large subset of prostate cancer patients with tumors that have already spread have a new chemotherapy-free treatment option. The FDA on Wednesday approved Lynparza, a PARP inhibitor from AstraZeneca (NYSE: AZN) and Merck (NYSE: MRK) that previously had been approved to treat people with ovarian and breast cancers. The FDA completed its review of Lynparza for prostate cancer patients with tumors that test positive for homologous recombination repair (HRR) mutations a couple of months ahead of schedule.
- Yahoo Finance
Sorrento Therapeutics CEO: We are not a 'pump and dump' scheme
Sorrento Therapeutics defends his company and some promising new technology to address the COVID-19 pandemic.
- Motley Fool
Better Buy: GlaxoSmithKline vs. Pfizer
Both companies are weathering the bear market well as they lead the race to develop the coronavirus vaccine. But which is the better buy?
- Zacks
J&J to Stop Sale of Talc-Based Baby Powder in North America
J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.
- Motley Fool
GlaxoSmithKline, Pfizer, and Shionogi's HIV Prevention Candidate Outperforms Gilead's Truvada
A study showed that cabotegravir works better than the current pre-exposure prophylaxis treatment, but there may be issues with getting it approved.
- Zacks
Glaxo's Long-Acting HIV Injection Effective Than Daily Pills
Glaxo's (GSK) long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral pills.
- Motley Fool
What's Behind Axsome Therapeutics' Miracle Pipeline?
Just what exactly is going on with this company, which has had success in nearly every single clinical trial it initiated in recent years?
- Yahoo Finance
Market pros have high hopes for a COVID-19 vaccine: Morning Brief
Top news and what to watch in the markets on Tuesday, May 19, 2020.
- Business Wire
Pfizer Prices $4,000,000,000 Debt Offering
Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of four tranches of notes:
Yahoo Finance VideoCoronavirus latest: Friday, May 22
CanSino Biologics, a Chinese vaccine company, announced on Friday that it saw strong, positive results from its phase one trials of a coronavirus vaccine, which it tested on 108 volunteers. Yahoo Finance’s Anjalee Khemlani joins The Final Round to break down the latest news about the coronavirus.
Yahoo Finance VideoThe race for a coronavirus treatment is fanning fears of 'vaccine nationalism'
Yahoo Finance’s Brian Sozzi, Alexis Christoforous, and Anjalee Khemlani discuss the latest coronavirus news and the race for a vaccine.
Yahoo Finance VideoFmr. CDC Official: 'we’re not cutting any corners' on COVID-19 vaccine development
Vanderbilt University School of Medicine,Professor of Medicine in the Division of Infectious Diseases Dr. William Schaffner joins Yahoo Finance’s Seana Smith to discuss the coronavirus, as a quarter of Americans say they are nervous about a vaccine, according to a new Reuters/Ipsos poll.
Yahoo Finance VideoJohns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example'
Johns Hopkins Center for Health Security Senior Scholar Dr. Amesh Adalja joins Yahoo Finance’s Seana Smith to discuss President Trump’s remarks that he is taking hydroxychloroquine as a preventative measure against COVID-19.
